Lexeo Therapeutics (NASDAQ:LXEO) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen lowered shares of Lexeo Therapeutics (NASDAQ:LXEO – Free Report) from a sell rating to a strong sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Several other brokerages have also recently commented on LXEO. Cantor Fitzgerald reiterated an “overweight” rating on shares of Lexeo Therapeutics in a research report on Thursday. Chardan Capital upgraded shares of Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Leerink Partners restated an “outperform” rating and set a $15.00 price objective on shares of Lexeo Therapeutics in a research report on Wednesday, September 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lexeo Therapeutics in a research note on Wednesday. Finally, Raymond James Financial reiterated a “strong-buy” rating on shares of Lexeo Therapeutics in a report on Tuesday, September 22nd. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $16.43.

View Our Latest Report on LXEO

Lexeo Therapeutics Stock Down 1.4%

NASDAQ LXEO traded down $0.04 on Friday, reaching $2.87. 446,906 shares of the stock traded hands, compared to its average volume of 1,297,739. The firm’s fifty day simple moving average is $3.38 and its 200 day simple moving average is $5.01. The company has a market cap of $235.48 million, a price-to-earnings ratio of -2.50 and a beta of 1.64. Lexeo Therapeutics has a 12 month low of $2.55 and a 12 month high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO – Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). As a group, equities research analysts forecast that Lexeo Therapeutics will post -1.22 EPS for the current fiscal year.

Hedge Funds Weigh In On Lexeo Therapeutics

Hedge funds have recently modified their holdings of the stock. Signaturefd LLC raised its position in shares of Lexeo Therapeutics by 5,159.1% during the third quarter. Signaturefd LLC now owns 8,362 shares of the company’s stock worth $28,000 after purchasing an additional 8,203 shares during the period. Legal & General Group Plc acquired a new position in shares of Lexeo Therapeutics in the 2nd quarter valued at $32,000. Abel Hall LLC acquired a new position in shares of Lexeo Therapeutics in the 3rd quarter valued at $43,000. Spark Investment Management LLC purchased a new position in Lexeo Therapeutics in the 2nd quarter worth about $70,000. Finally, Canada Pension Plan Investment Board purchased a new position in Lexeo Therapeutics in the 2nd quarter worth about $86,000. 60.67% of the stock is currently owned by institutional investors and hedge funds.

About Lexeo Therapeutics

(Get Free Report)

Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations. The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.

Recommended Stories

Analyst Recommendations for Lexeo Therapeutics (NASDAQ:LXEO)

Receive News & Ratings for Lexeo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexeo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.